VIDEO: Real-world data explore treatment extension for aflibercept 8 mg

ByDavid A. Eichenbaum, MD

ByEamon N. Dreisbach

ByDavid W. Mullin

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David A. Eichenbaum, MD, presents real-world data related to the use of aflibercept 8 mg.

Patients from two retina clinics who received aflibercept 8 mg with at least 6 months of follow-up were included.

“Overall, what we saw in this whole population is patients in general can extend if they have been previously treated on aflibercept 8 mg to longer than their previous injection interval on average,” he said. “We see that some patients, about a third, are extremely responsive, and about a quarter of patients aren’t really good candidates for aflibercept 8 mg out to 7 or 8 weeks.”

Published by:

Sources/Disclosures

Collapse

Source:

Eichenbaum DA. Early real-word experience with aflibercept 8 mg. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Eichenbaum reports being a speaker, consultant and investigator for Bayer, Genentech, Regeneron and Roche.

Clinical Trials at the Summit meeting

Read more

VIDEO: Real-world data explore treatment extension for aflibercept 8 mg

Related Content